ATE423559T1 - Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren - Google Patents

Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren

Info

Publication number
ATE423559T1
ATE423559T1 AT02717766T AT02717766T ATE423559T1 AT E423559 T1 ATE423559 T1 AT E423559T1 AT 02717766 T AT02717766 T AT 02717766T AT 02717766 T AT02717766 T AT 02717766T AT E423559 T1 ATE423559 T1 AT E423559T1
Authority
AT
Austria
Prior art keywords
combination therapy
ppar modulators
absorption inhibitors
glucose absorption
ppar
Prior art date
Application number
AT02717766T
Other languages
English (en)
Inventor
Jacqueline Bussolari
Xiaoli Chen
Bruce Conway
Keith Demarest
Hamish Ross
Rafael Severino
Original Assignee
Ortho Mcneil Janssen Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Janssen Pharm filed Critical Ortho Mcneil Janssen Pharm
Application granted granted Critical
Publication of ATE423559T1 publication Critical patent/ATE423559T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A61K31/31—Mercury compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
AT02717766T 2001-04-04 2002-04-03 Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren ATE423559T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28142901P 2001-04-04 2001-04-04

Publications (1)

Publication Number Publication Date
ATE423559T1 true ATE423559T1 (de) 2009-03-15

Family

ID=23077253

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02717766T ATE423559T1 (de) 2001-04-04 2002-04-03 Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren

Country Status (11)

Country Link
US (3) US20030045553A1 (de)
EP (2) EP2065044A1 (de)
JP (1) JP4590159B2 (de)
CN (1) CN100577175C (de)
AT (1) ATE423559T1 (de)
CA (1) CA2442917C (de)
DE (1) DE60231295D1 (de)
ES (1) ES2321815T3 (de)
MY (1) MY180762A (de)
TW (1) TWI330084B (de)
WO (1) WO2002080936A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE423559T1 (de) 2001-04-04 2009-03-15 Ortho Mcneil Janssen Pharm Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren
JP4590158B2 (ja) * 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
US20090162342A1 (en) * 2001-06-07 2009-06-25 Sanomune Inc. Therapeutic uses of glandular kallikrein
EP1388352A1 (de) * 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Verwendung eines ppar-alpha-Agonisten zur Behandlung von Patienten, die an mit ppar-gamma-Agonisten-Behandlung assozierter Fettleibigkeit leiden
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) * 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
JP2004300102A (ja) * 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
US7601756B2 (en) * 2003-06-06 2009-10-13 Snowden Pharmaceuticals, Llc Method of treatment for irritable bowel syndrome
BRPI0412009A (pt) * 2003-06-27 2006-08-15 Reddy Research Foundation composições compreendendo balaglitazona e outros compostos antidiabéticos
US7691420B2 (en) * 2003-09-23 2010-04-06 Dsm Ip Assets B.V. Compositions for the treatment and prevention of diabetes mellitus
US20050239706A1 (en) * 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
EP1707195A4 (de) * 2004-01-23 2007-06-20 Japan Science & Tech Agency Retinolsäureenthaltendes heilmittel für diabetes
EP1714648A4 (de) * 2004-02-09 2010-05-26 Aska Pharm Co Ltd Kombinationsarzneimittel
US9421175B2 (en) 2004-03-17 2016-08-23 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
ES2581331T3 (es) 2004-07-21 2016-09-05 Kissei Pharmaceutical Co., Ltd. Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
EP1853258A4 (de) * 2005-03-03 2008-05-07 Smithkline Beecham Corp Medikamente
US20080280955A1 (en) * 2005-09-30 2008-11-13 Perlegen Sciences, Inc. Methods and compositions for screening and treatment of disorders of blood glucose regulation
EP1785133A1 (de) * 2005-11-10 2007-05-16 Laboratoires Fournier S.A. Verwendung von Fenofibrate oder dessen Derivaten zur Prävention von diabetischer retinopathie
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
WO2008096769A1 (ja) * 2007-02-08 2008-08-14 Daiichi Sankyo Company, Limited 置換されたセルコスポラミド誘導体を含有する医薬
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
US8666671B2 (en) * 2007-07-05 2014-03-04 Enhanced Pharmaceuticals, Inc. Method for determining drug-molecular combinations that modulate and enhance the therapeutic safety and efficacy of biological or pharmaceutical drugs
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
MX2010007426A (es) * 2008-01-31 2010-08-18 Astellas Pharma Inc Composiciones farmaceuticas para tratar trastorno del higado graso.
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
SI2334687T1 (sl) * 2008-08-28 2012-03-30 Pfizer Dioksa biciklo oktan triol derivati
KR20120016051A (ko) * 2009-04-16 2012-02-22 다이쇼 세이야꾸 가부시끼가이샤 제약 조성물
EP2451455A4 (de) * 2009-07-10 2013-01-16 Univ Case Western Reserve Rxr-agonisten-verbindungen und -verfahren
RU2012117560A (ru) 2009-10-02 2013-11-10 Санофи Применение соединений с активностью ингибиторов sglt-1/sglt-2 для получения лекарственных средств для лечения заболеваний костей
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
ES2527179T3 (es) 2009-11-02 2015-01-21 Pfizer Inc. Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2543357B1 (de) * 2011-07-07 2018-03-21 Holy Stone Healthcare Co.,Ltd. Zusammensetzung zur Verwendung bei der Behandlung und Vorbeugung von entzündungsbedingten Störungen
US9451987B2 (en) 2011-11-16 2016-09-27 K2M, Inc. System and method for spinal correction
WO2013173923A1 (en) 2012-05-25 2013-11-28 Diamedica, Inc. Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
CA2880085C (en) 2012-06-04 2021-09-07 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
CN102727477B (zh) * 2012-06-14 2014-07-16 合肥博太医药生物技术发展有限公司 视黄酸及其衍生物在制备防治糖尿病药物中的应用
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
KR20190122706A (ko) 2017-03-09 2019-10-30 다이어메디카 인코포레이티드 조직 칼리크레인 1의 투약 형태
EP3733203A4 (de) * 2017-12-28 2021-08-25 University of Fukui Prophylaktisches mittel und/oder therapeutisches mittel für katarakt, medizinische zusammensetzung zur vorbeugung und/oder behandlung von katarakt, verwendung von ppar-aktivator zur herstellung davon und augentropfen
CN111437393B (zh) * 2020-04-30 2021-03-02 深圳微芯生物科技股份有限公司 用于糖尿病及其并发症治疗的联合用药及其药物组合物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
SG59988A1 (en) * 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
JPH0253573A (ja) * 1988-08-11 1990-02-22 Nippon Riki Kk ラチェットレンチの製造法
US5731299A (en) 1992-05-29 1998-03-24 The Procter & Gamble Company Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
JP2762903B2 (ja) 1992-11-12 1998-06-11 田辺製薬株式会社 ジヒドロカルコン誘導体及びその製法
US5731292A (en) * 1992-11-12 1998-03-24 Tanabe Seiyaku Co., Ltd. Dihydrochalcone derivatives which are hypoglycemic agents
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
JP2795162B2 (ja) 1993-02-18 1998-09-10 田辺製薬株式会社 ジヒドロカルコン誘導体及びその製法
JP2906978B2 (ja) * 1993-02-25 1999-06-21 田辺製薬株式会社 血糖降下剤
US6046222A (en) 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
JP2847695B2 (ja) * 1994-05-11 1999-01-20 田辺製薬株式会社 血糖降下剤
US5830873A (en) * 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
DK0859608T3 (da) 1995-09-18 2004-06-14 Ligand Pharm Inc Behandling af NIDDM med RXR-agonister
JP3059088B2 (ja) * 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP2000514807A (ja) * 1996-07-12 2000-11-07 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー レプチン耐性の新規な治療
TW406086B (en) 1996-12-26 2000-09-21 Tanabe Seiyaku Co Propiophenone derivatives and process for preparing the same
JP3055135B2 (ja) * 1996-12-26 2000-06-26 田辺製薬株式会社 プロピオフェノン誘導体及びその製法
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
JP4100734B2 (ja) 1997-04-30 2008-06-11 Ｓａｂｉｃイノベーティブプラスチックスジャパン合同会社 熱可塑性樹脂組成物
BR9810186A (pt) 1997-06-18 2000-08-08 Smithkline Beecham Plc Tratamento de diabete com tiazolidinadiona e inibidor de alfa-glicosidade
JP2000080041A (ja) 1998-03-09 2000-03-21 Tanabe Seiyaku Co Ltd 医薬組成物
EP1131310B1 (de) * 1998-11-20 2006-01-11 Mitsubishi Chemical Corporation 5-[(6-(2-fluorbenzyl)oxy-2-naphtyl)methyl]-thiazolid in-2,4-dion kristallen
US6337426B1 (en) 1998-11-23 2002-01-08 Nalco/Exxon Energy Chemicals, L.P. Antifoulant compositions and processes
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
WO2000065052A1 (en) 1999-04-22 2000-11-02 Habener Joel F Bridge-1, a transcription factor
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
UA71994C2 (en) 1999-08-31 2005-01-17 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives, a pharmaceutical composition containing these derivatives and intermediate compounds for the preparation thereof
US6515003B1 (en) 1999-08-31 2003-02-04 Maxia Pharmaceuticals, Inc. Heterocyclic derivatives for the treatment of diabetes and other diseases
PE20010580A1 (es) 1999-09-03 2001-05-25 Takeda Chemical Industries Ltd Composicion farmaceutica para tratar la diabetes
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
JP2001192375A (ja) * 1999-10-29 2001-07-17 Takeda Chem Ind Ltd オキシイミノアルカン酸誘導体の結晶
TW558554B (en) 1999-10-29 2003-10-21 Takeda Chemical Industries Ltd Crystals of oxyiminoalkanoic acid derivative
MXPA02004647A (es) * 1999-11-10 2002-10-31 Takeda Chemical Industries Ltd Compuestos heterociclicos de 5 miembros que contienen nitrogeno.
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
AU2002253838B2 (en) 2000-10-30 2006-11-09 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising anti-diabetic and anticonvulsant agents
NZ526715A (en) 2000-12-28 2005-02-25 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives and use thereof in medicines
JP4590158B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
ATE423559T1 (de) 2001-04-04 2009-03-15 Ortho Mcneil Janssen Pharm Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren

Also Published As

Publication number Publication date
WO2002080936A1 (en) 2002-10-17
TWI330084B (en) 2010-09-11
US8278268B2 (en) 2012-10-02
US20030045553A1 (en) 2003-03-06
EP1381361B1 (de) 2009-02-25
MY180762A (en) 2020-12-08
CN100577175C (zh) 2010-01-06
US20030199557A1 (en) 2003-10-23
ES2321815T3 (es) 2009-06-12
JP4590159B2 (ja) 2010-12-01
DE60231295D1 (de) 2009-04-09
JP2004529915A (ja) 2004-09-30
EP2065044A1 (de) 2009-06-03
EP1381361A1 (de) 2004-01-21
CA2442917C (en) 2011-02-01
CN1568190A (zh) 2005-01-19
US20080096802A1 (en) 2008-04-24
CA2442917A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
ATE423559T1 (de) Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren
ATE442148T1 (de) Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
PT1333887E (pt) Metodo de tratamento de desordens musculares
PL374865A1 (en) Treatment of tnf alpha related disorders
PT1349856E (pt) Compostos de isoindolina-1-ona activadores da glicocinase
IL194950A0 (en) Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
ATE364386T1 (de) (s,s)-reboxetine zur behandlung von chronischen erschöpfungssyndrom
NO20041917L (no) Spesifikke midler som binder humant angiopoietin-2
DK1414486T3 (da) Anvendelse af GLP-2 i kombination med et andet terapeutisk middel ved knoglerelaterede sygdomme
ATE410165T1 (de) Nociceptin-analoga
EA200500098A1 (ru) Лекарственное средство и способ лечения патологического синдрома
NO20022087L (no) Fremgangsmåte for behandling av diabetes
DK1429756T3 (da) Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
NO20045554L (no) Fremgangsmate for behandling av diabetes
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
ATE346614T1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
NO20051847L (no) Eikosapentaensyre (EPA) for behandling av anoreksia nevrosa (AN) og bulimi.
NO20051521L (no) Anvendelse av kombinasjonen av ciclesonid og antihistaminer for behandlingen av allergisk rhinitt
NO20034123L (no) Fremgangsmåte for behandling av brennstoff
FI20011298L (fi) Puunkäsittelyliuos ja menetelmä puun säilyvyyden parantamiseksi
SE0103276L (sv) Anordning för administrering av salva till en hudyta
DK1530462T3 (da) 1-phenyl-2-dimethylaminomethylcyclohexanforbindelser til behandling af depressionssymtomer. smerte og inkontinens
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
DK1366033T3 (da) Kemiske forbindelser
DK0673902T3 (da) Middel til behandling af bioaffald

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties